Is Bayer CropSci. overvalued or undervalued?

As of 17 October 2025, Bayer CropScience has moved from a valuation grade of very expensive to expensive. The company is currently considered overvalued based on its key financial metrics. The PE ratio stands at 38.24, while the EV to EBITDA ratio is 30.04, and the Price to Book Value is 7.95, all indicating a premium valuation compared to its peers.
In comparison to its industry peers, Bayer CropScience's valuation appears high, especially when looking at UPL with a PE ratio of 37.91 and BASF India at 47.93. Additionally, the PEG ratio for Bayer is notably low at 0.00, suggesting that growth expectations may not justify the current price. Recent performance has also been underwhelming, with a year-to-date return of -9.24%, significantly lagging behind the Sensex's 7.44% return.